Clonal hematopoiesis arises when a hematopoietic stem or progenitor cell acquires a mutation — commonly in genes such as DNMT3A, TET2, ASXL1, TP53, or JAK2 — and its descendants expand to occupy a measurable fraction of the blood cell population. The phenomenon becomes increasingly prevalent with age, and its presence in apparently healthy people without hematologic malignancy is termed clonal hematopoiesis of indeterminate potential, or CHIP. When cytopenias are also present, the designation shifts to clonal cytopenia of undetermined significance. The critical issue for oncology is that these mutations are indistinguishable, at the sequence level, from somatic alterations driving cancer. A TP53 variant detected in a plasma sample from a patient with suspected lung cancer could be a genuine tumor-derived alteration circulating as cell-free DNA, or it could be leaking into the assay from a large clone of mutated white blood cells. The distinction changes everything about how the result is interpreted and acted upon.

The review’s first domain, Domain A, addresses variant-origin assessment, and here the authors are emphatic about the hierarchy of evidence. Matched white blood cell sequencing provides the most direct comparator: if a variant detected in tumor tissue or plasma is also present in the patient’s leukocytes, a hematopoietic source is strongly supported. This paired-specimen approach is technically straightforward but is not yet universally practiced, particularly in plasma-based assays where white blood cell sequencing is often omitted for cost or workflow reasons. When matched sequencing is unavailable, the authors note that complementary lines of evidence can help — concordance between the variant in tumor and plasma, longitudinal dynamics of the variant over time, fragmentomic features of the cell-free DNA molecules carrying it, and appropriately validated computational models that attempt to infer tissue of origin. But they insist on a crucial epistemic rule: when the origin of a variant cannot be resolved, it should remain classified as indeterminate rather than being forced into a tumor or blood category for the sake of a complete report.

The consequences of failing to make this distinction ripple through every layer of modern molecular oncology. Tumor genotyping can be distorted when hematopoietic contamination inflates apparent mutation frequencies or introduces variants that were never present in the cancer cells themselves. Circulating tumor DNA interpretation, the backbone of noninvasive genotyping and treatment selection, is vulnerable to false positives from leukocyte-derived cell-free DNA. Perhaps most consequential is molecular residual disease assessment, the rapidly growing practice of using ultra-sensitive ctDNA assays after surgery or curative-intent therapy to detect microscopic residual cancer. A persistent hematopoietic clone shedding cell-free DNA can mimic residual disease, potentially triggering unnecessary adjuvant treatment, or conversely can mask true tumor signal. The review frames these risks not as theoretical curiosities but as systematic threats that demand workflow-level solutions, including routine paired white blood cell sequencing as a standard component of liquid biopsy pipelines.

Domain B of the framework shifts perspective entirely. Once a variant has been established as hematopoietic in origin, clonal hematopoiesis ceases to be a source of error and becomes a candidate host variable — a feature of the patient rather than the tumor. But the authors warn against treating it as a single binary attribute. They enumerate the structured dimensions that must be captured for any meaningful analysis: the genotype, meaning the specific mutated gene; the exact variant within that gene, since different mutations in the same gene can have different functional consequences; the clone size, typically estimated by variant allele fraction in blood; co-detected alterations within the same clone or in parallel clones; the lineage contribution, meaning which blood cell types the clone has infiltrated; prior treatment exposures such as chemotherapy or radiotherapy that may select for or against particular clones; the timing of sampling relative to diagnosis and therapy; and longitudinal behavior, whether the clone is expanding, contracting, or stable. A TET2-mutant clone at two percent variant allele fraction that has been stable for years is, in this framework, a fundamentally different biological entity from a TP53-mutant clone at fifteen percent that emerged after cytotoxic chemotherapy.

Domain C confronts the seductive hypothesis that clonal hematopoiesis might serve as a prognostic or predictive biomarker in solid-tumor care. The biological plausibility is real: mutated hematopoietic clones, particularly those with TET2 loss, have been shown in mechanistic studies to alter inflammatory signaling and immune function, including through elevated production of inflammatory cytokines and altered macrophage polarization. This has fueled speculation that patients carrying such clones might respond differently to immune checkpoint inhibitors, the checkpoint-blocking antibodies that have transformed treatment of many advanced cancers. The review does not dismiss this hypothesis, but it imposes demanding methodological standards on any study claiming clinical relevance: prespecified features and endpoints declared before analysis, appropriate comparator groups, rigorous control of confounding — a formidable challenge given that clonal hematopoiesis prevalence rises with age, smoking exposure, and therapy history, all of which independently influence cancer outcomes — external validation in independent cohorts, and demonstration of incremental value beyond established tumor and clinical factors already in use.

On the specific question of TET2-mutant clonal hematopoiesis and immunotherapy, the authors draw a line that many in the field will find uncomfortable but necessary. The mechanistic evidence linking TET2 loss to altered antitumor immunity is genuine but model-limited, derived largely from preclinical systems and observational associations. It does not, they argue, constitute a validated basis for selecting or deselecting patients for immune checkpoint inhibitor therapy. In other words, a clinician who sees a TET2 mutation in a patient’s blood panel today should not conclude that the patient will respond better or worse to pembrolizumab or nivolumab. The framework’s insistence on separating biological activity from clinical actionability is perhaps its most important contribution, because the history of biomarker development is littered with plausible mechanisms that failed to survive prospective validation.

Domain D addresses intervention, and here the framework is at its most conservative. For clonal hematopoiesis to justify any therapeutic intervention in the context of solid-tumor care, the authors require a target that is causal in the disease process, measurable with available tools, and safely modifiable — plus evidence of clinical utility and net patient benefit. None of these conditions is currently met. Even in hematology, where CHIP and clonal cytopenia are native concepts, intervention thresholds remain debated, and the idea of treating blood clones to improve cancer outcomes sits far beyond the current evidence base. The authors’ point is not that such interventions are impossible but that the field must resist the temptation to leap from association to action, a leap that has historically produced harm when premature.

The review’s conclusions amount to a roadmap with explicit guardrails. In the near term, laboratories and clinicians should implement origin-aware molecular interpretation: paired white blood cell sequencing where feasible, transparent reporting of variant-origin confidence, and honest preservation of indeterminate classifications rather than forced attributions. In the medium term, the authors call for prospective evaluation of paired-specimen workflows to quantify how much diagnostic accuracy improves when hematopoietic variants are systematically identified, and for genotype-resolved studies of clonal hematopoiesis as a host variable, since pooling all mutations under a single label almost certainly obscures the biology. The framework, published as an open-access article in the Journal of Translational Medicine, arrives at a moment when liquid biopsy volumes are expanding rapidly and molecular residual disease testing is moving toward routine use in early-stage cancers. Whether the field adopts the discipline the authors prescribe may determine whether clonal hematopoiesis becomes a precision oncology asset — or a persistent, avoidable source of misdiagnosis.

Subject of Research: Clonal hematopoiesis as a source of variant misattribution and a candidate host biomarker in solid-tumor precision oncology

Article Title: Clonal hematopoiesis in solid-tumor precision oncology: an intended-use framework for variant-origin assessment, host biomarker evaluation, and intervention boundaries

Article References: Yang, Y., Fu, J., Tang, S., Wen, L., Hu, H., Guo, H., Yang, Y., Liu, C., Yi, G., Yu, L., & Zhou, H. (2026). Clonal hematopoiesis in solid-tumor precision oncology: an intended-use framework for variant-origin assessment, host biomarker evaluation, and intervention boundaries. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08963-9

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08963-9

Keywords: clonal hematopoiesis, CHIP, precision oncology, liquid biopsy, circulating tumor DNA, molecular residual disease, variant-origin assessment, TET2, immune checkpoint inhibitors, cell-free DNA, biomarker evaluation, white blood cell sequencing